Welcome to our dedicated page for Adia Med news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Med stock.
ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
Adia Med (OTCQB: ADIA) reported second-quarter 2026 revenue of approximately $485,000, up about 175% sequentially from $176,275 in Q1 2026, and achieved its first quarterly net income of roughly $40,000. First-half 2026 revenue reached $661,660, almost matching the company’s full-year 2025 revenue of about $700,508.
According to Adia Med, growth was supported by higher patient volume for regenerative treatments, expanded commercialization of Adia Labs biologic products such as AdiaVita™, and operational efficiencies that improved gross margins. The company completed Phase 1 and began Phase 2 of its Autism Spectrum Disorder study and is advancing additional Chronic Kidney Disease and orthopedic studies.
Adia Med (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, announced an educational partnership with Full Sail University in Winter Park, Florida. As part of the collaboration, CEO Larry Powalisz will present the company at Full Sail's Auditorium on August 13, 2026 at 1:00 p.m. to both in-person and online students.
The presentation will introduce Adia Med, its mission in regenerative medicine, and current growth, with a primary focus on exploring how Full Sail students can assist with SEO, social media, and marketing. Students may use Adia Med as a real-world class project or apply as non-paid interns supporting digital marketing, social media, content, and SEO initiatives. The partnership is intended to provide hands-on experience for students while giving Adia Med access to fresh creative talent and enhanced online presence.
Adia Med (OTCQB: ADIA) will host a private dinner for physicians and investors on Wednesday, August 5, 2026 at 7:00 PM at Christner's Steakhouse in Winter Park, Florida. The event will cover Adia Med's current clinical studies, including its Autism Spectrum Disorder research and other regenerative medicine initiatives, highlight patient referral and recruitment opportunities, and outline ways for physicians to participate as Co-Investigators or Principal Investigators. Interested attendees are asked to contact CEO Larry Powalisz for details and to RSVP.
Adia Med (OTCQB: ADIA) reported completion of Phase 1 treatment for the first cohort of 30 children (ages 3–12) in its Autism Spectrum Disorder clinical study (NCT07304440) and the formal launch of Phase 2 for that cohort.
After Institutional Review Board permission, Adia Med shortened Phase 1 by one month, enabling earlier completion of the initial interventional phase, which began May 1, 2026. The randomized 12‑month Phase 1/2 trial compares AdiaVita (umbilical cord blood‑derived stem cells and exosomes) plus glutathione against glutathione alone, with primary outcomes based on changes in Autism Treatment Evaluation Checklist (ATEC) scores.
New cohorts of 30 children are scheduled every three months, with the next Phase 1 group starting October 1, 2026, under Dr. Thomas. The study targets approximately 100 children, remains fully investigational, and makes no claims of treating, curing, or preventing ASD, according to Adia Med.
Adia Med (OTCQB: ADIA), a clinical-stage regenerative medicine company, has launched a redesigned corporate website at www.adiamed.com, which now serves as its primary digital hub following the recent name change from Adia Nutrition to Adia Med.
The site highlights clinical studies, stem cell therapies, and aesthetics, and includes or is planned to include sections for media coverage, podcasts and video interviews, clinical case studies, investor information and regulatory filings, company news, and educational resources. The former site, www.adianutrition.com, now automatically redirects to the new platform, which the company says is still being enhanced and aims to improve transparency and accessibility for patients, healthcare professionals, media, and investors.
Adia Med (OTCQB: ADIA) outlines milestones since its January 2024 leadership change, when Larry Powalisz became CEO and bootstrapped a new regenerative medicine strategy. The company acquired and later divested Biolete, secured an 18% stake in Cement Factory, created subsidiaries Adia Med of Winter Park and Adia Labs, and removed its shell status effective June 30, 2024.
By January 2025, Adia Med opened its flagship Winter Park clinic, began treating patients, and in May 2025 retired over 25 million improperly issued shares via court settlement. According to Adia Med, revenue reached $637,145 in the first nine months of 2025, driven by biologics and clinic procedures. The company gained FDA registration for its biologics, filed a provisional patent, and was uplisted to the OTCQB Venture Market in 2025.
Adia Med obtained IRB approvals and ClinicalTrials.gov registration for autism spectrum disorder (ASD), chronic kidney disease, and lower back pain studies, with ASD treatments starting May 1, 2026. With Form 10 effective on February 3, 2026 and a name change advancing through FINRA, the company targets a future NASDAQ uplisting, citing remaining shareholder equity and net revenue requirements.
Adia Nutrition (OTCQB: ADIA) will begin trading as Adia Med Inc. following an expedited FINRA review of its corporate name change. The new name appears on the FINRA Daily List today, with trading under Adia Med Inc. expected to start July 10, 2026, on OTC Markets.
According to the company, the new name aligns with its focus on stem cell and regenerative therapies.
Adia Nutrition (OTCQB: ADIA) announced it has entered the final stage of its corporate name change process to Adia Med. After several months of FINRA review and three comment rounds, the company believes all requirements are satisfied and expects FINRA approval in the coming weeks.
Adia Med (OTCQB: ADIA) highlighted a new podcast where CEO Larry Powalisz interviews Dr. Lyday, a physician known for supporting stem cell-based treatments. Powalisz calls her a clinical "unicorn" who both researches and applies regenerative medicine.
The discussion covers stem cells, exosomes, clinical uses for conditions including Lyme disease, safety issues, and the future of regenerative medicine, aligning with Adia Med’s mission and its AdiaVita product line. The full episode is available on YouTube.
Adia Med (OTCQB: ADIA) is enhancing IV therapy quality by having Lead Physician Dr. Brian Browning train APRNs and RNs in ultrasound-guided IV insertions using the Butterfly portable ultrasound device.
The program targets more precise, reliable, and comfortable IV access, especially for patients with difficult veins, and supports Adia Med’s regenerative and nutrient therapies, including stem cell, exosome, glutathione, and other precision wellness infusions.